Log in

NASDAQ:XBIOXenetic Biosciences Stock Price, Forecast & News

-0.03 (-3.03 %)
(As of 06/2/2020 04:00 PM ET)
Today's Range
Now: $0.96
50-Day Range
MA: $0.92
52-Week Range
Now: $0.96
Volume116,298 shs
Average Volume347,644 shs
Market Capitalization$6.03 million
P/E RatioN/A
Dividend YieldN/A
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.
Read More
Xenetic Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.47 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:XBIO



Sales & Book Value

Annual Sales$20,000.00
Book Value$2.84 per share


Net Income$-12,770,000.00


Market Cap$6.03 million
Next Earnings Date8/20/2020 (Estimated)
OptionableNot Optionable

Receive XBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.

Xenetic Biosciences (NASDAQ:XBIO) Frequently Asked Questions

How has Xenetic Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Xenetic Biosciences' stock was trading at $0.7031 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, XBIO shares have increased by 40.1% and is now trading at $0.9849. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Xenetic Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Xenetic Biosciences.

When is Xenetic Biosciences' next earnings date?

Xenetic Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Xenetic Biosciences.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.18. The business had revenue of $0.06 million for the quarter. View Xenetic Biosciences' earnings history.

What price target have analysts set for XBIO?

2 equities research analysts have issued 12 month price objectives for Xenetic Biosciences' shares. Their forecasts range from $2.50 to $2.50. On average, they anticipate Xenetic Biosciences' stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 153.8% from the stock's current price. View analysts' price targets for Xenetic Biosciences.

Has Xenetic Biosciences been receiving favorable news coverage?

News articles about XBIO stock have trended extremely negative on Wednesday, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Xenetic Biosciences earned a news impact score of -4.6 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutXenetic Biosciences.

Who are some of Xenetic Biosciences' key competitors?

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Amarin (AMRN), Inovio Pharmaceuticals (INO), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Achieve Life Sciences (ACHV), Agile Therapeutics (AGRX), Aytu Bioscience (AYTU) and Biocept (BIOC).

Who are Xenetic Biosciences' key executives?

Xenetic Biosciences' management team includes the following people:
  • Mr. Jeffrey F. Eisenberg, CEO & Director (Age 53)
  • Mr. James F. Parslow, CFO, COO & Corp. Sec. (Age 54)
  • Dr. Curtis A. Lockshin, Chief Scientific Officer (Age 59)

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

Who are Xenetic Biosciences' major shareholders?

Xenetic Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sabby Management LLC (0.96%).

Which institutional investors are selling Xenetic Biosciences stock?

XBIO stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC.

How do I buy shares of Xenetic Biosciences?

Shares of XBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $0.98.

How big of a company is Xenetic Biosciences?

Xenetic Biosciences has a market capitalization of $6.19 million and generates $20,000.00 in revenue each year. Xenetic Biosciences employs 4 workers across the globe.

What is Xenetic Biosciences' official website?

The official website for Xenetic Biosciences is www.xeneticbio.com.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The company can be reached via phone at 781-778-7720 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.